Kornimate/medical-research-clean huggingface dataset:
expreson-in : intracerebral recordings of p3a responses to expressive own-names

Conditions: Intractable Epilepsy

Summary: neurophysiologic evaluation of disorders of consciousness (doc) patients in intensive care unit include late auditory evoked potentials. it allows the physicians to record cerebral responses of patients to auditory stimuli and in particularly to their own name (as the p3a response). numerous studies try to improve the relevance of the auditory stimuli used in this paradigm and notably using more expressive stimuli. here the investigators investigate the intracerebral correlates of the p3a responses recorded on the scalp with neutral and more expressive stimuli.

late auditory evoked potentials (as p3 wave) are used in neurophysiology to assess the level of consciousness in doc (disorder of consciousness) patients. the p3 wave, elicited by listening standard and deviant stimuli, corresponds to the activation of a frontoparietal network and is considered to reflect a cognitive attention task. using the own name of the patient as deviant stimuli improve the ability to detect the p3 wave because of the particularly relevance of this stimulus for the patient. in human cognition, to identify the expressivity valence of a voice is essential. neural processing of expressive voices should involves more widespread brain areas than neutral voices processing. here the investigators investigate the intracerebral correlates of the p3a responses recorded on the scalp to own-name stimuli uttered by neutral and more expressive voices (positive : smiling voice or negative : rough voice) in adult pharmacoresistant epilepsy patients.

Eligibility criteria:
inclusion criteria: * intractable focal epilepsy with undergoing pre-surgical evaluation * intracerebral electrodes implantation in auditory cortices, temporal lobe, superior temporal gyrus, limbic areas, frontal lobe * given consent to inclusion exclusion criteria: * deafness * pregnancy

Keywords: event-related potentials (erp) intracerebral recordings presurgical evaluation
validating the safety and effectiveness of endoangel lower gastrointestinal endoscope image auxiliary diagnostic software

Conditions: Intestinal Polyps

Summary: to evaluate the safety and effectiveness of endoangel lower gastrointestinal endoscope image auxiliary diagnostic software developed and manufactured by wuhan endoangel medical technology co., ltd.


Eligibility criteria:
inclusion criteria: * 18 years old ≤ age ≤ 75 years old, male or female; * subjects with colonoscopy diagnosis and screening needs; * sign the written informed consent form; * with full capacity for civil conduct. exclusion criteria: * history of acute myocardial infarction (within 6 months), severe heart, liver, and renal insufficiency or mental disease; * patients who are taking aspirin, warfarin, and other anticoagulants; * patients with inflammatory bowel disease, or polyposis syndromes, or confirmed or highly suspected colon cancer; * history of colorectal surgery; * patients with familial adenomatous polyposis; * pregnant women (if the subject is a woman of reproductive age and cannot confirm whether she is pregnant, a pregnancy test is required); * patients who are participating in clinical trials of other drugs or medical devices; * patients who are not eligible to participate in this clinical trial in the opinion of the investigator.
effect of early rehabilitation on recovery following abdominal hysterectomy

Conditions: Post-Op Complication

Summary: variety of physical therapy treatments have been used after open abdominal surgery to improve cardiopulmonary and physical function as well as to reduce the incidence of postoperative pulmonary complications. this study intends to determine the effect of early physical therapy interventions on post-operative recovery profile, post-operative ileus and incisional pain following abdominal hysterectomy.

this study is randomized controlled trial which will be conducted at in-patient gynecology department of pakistan railway hospital. this study would include total of 42 participants divided into two groups with 21 participants in each group calculated through openepi (ci=95%power=80%). individuals will be screened according to inclusion and exclusion criteria and allocated randomly into two groups through sealed envelope method. experimental group will receive early physical therapy interventions including patient education, ambulation, in-bed exercises, deep breathing exercises, connective tissue manipulation and tens during the first 3 post-operative days following abdominal hysterectomy. while the control group will receive patient education and early ambulation during the first 3 post-operative days following abdominal hysterectomy. post-operative recovery will be assessed on 3rd post-operative day. intensity of pain will be measured on baseline and 3rd post-operative day. the effect of intervention on post-operative ileus will be measured by monitoring each participant's time to tolerance of oral diet, first passage of stool and flatus

Eligibility criteria:
inclusion criteria: * open abdominal hysterectomy * patient awake and responsive, stable blood pressure, stable heart rate, no dyspnea at rest and pain score \< 8 on visual analogue scale on first post-operative day. * no limitation on physical activities due to any medical problem or restriction by the physician. exclusion criteria: * other hysterectomy procedures i.e. laparoscopic or vaginal hysterectomy. * females with diabetes or cancer of metastatic nature. * neurological or cognitive deficit. * ongoing respiratory problem prior to initiation of physical therapy session. * medical recommendation not to participate in early active rehabilitation

Keywords: abdominal hysterectomy postoperative pain early rehabilitation postoperative recovery profile
docetaxel/carboplatin versus docetaxel/caelyx in pretreated patients with ovarian carcinoma

Conditions: Ovarian Cancer

Summary: this trial will compare the efficacy of docetaxel/carboplatin versus docetaxel/liposomal doxorubicin in pretreated patients with advanced ovarian carcinoma and treatment free-interval of at least six months

the second-line treatment in advanced ovarian cancer has been proved effective in prolonging overall survival and improving quality of life. in patients with platinum-sensitive ovarian cancer (relapsed disease after 6 months from the end of first line chemotherapy) the combination of paclitaxel/carboplatin is considered the standard treatment. generally, the combination platinum-based chemotherapy may well be associated with a survival benefit in patients with platinum-sensitive disease. carboplatin, pegylated doxorubicin (caelyx) docetaxel, have been approved for second-line treatment of ovarian carcinoma and seem to be active in platinum-sensitive disease.

Eligibility criteria:
inclusion criteria: * histologically confirmed ovarian cancer * stage iiib/iv * failure to prior chemotherapy with paclitaxel /carboplatin regimen and treatment free interval \> 6 months * presence of two-dimensional measurable disease. * life expectancy of more than 3 months. * age ≥ 18 years. * performance status (who) 0-2 * adequate bone marrow function (absolute neutrophil count \>1000/mm\^3, platelet count\>100000/mm\^3, hemoglobin\>9gr/mm\^3) * adequate liver (bilirubin\<1.5 times upper limit of normal and sgot/sgpt\<2 times upper limit of normal) and renal function (creatinine\<2mg/dl) * informed consent exclusion criteria: * pregnant or nursing * psychiatric illness or social situation that would preclude study compliance' * other concurrent uncontrolled illness * other invasive malignancy within the past 5 years except nonmelanoma skin cancer * other concurrent investigational agents

Keywords: cancer ovarian cancer chemotherapy docetaxel carboplatin pegylated doxorubicin platinum sensitive
residual insulin secretion in patients with type 1 diabetes under a low carbohydrate diet or a ketogenic diet

Conditions: Type1 Diabetes

Summary: low carbohydrate diet (lcd) (\< 130 g of carbohydrate per day) and ketogenic diet (\< 50 g of carbohydrate per day) are popular among patients with type 1 diabetes (t1d). in most cases, lcd allow a better glycemic control and a important decrease of insulin requirements that cannot, however, be the sole result of low carbohydrate intake. however, due to the increase production of ketone bodies and the decrease of the insulin/glucagon rate, this diet is not without risk in t1d patients and some of them develop ketoacidosis. type 1 diabetes is a autoimmune disease defined by the destruction of the pancreatic beta cells by the effector t cells, in condition of low regulatory t cells (tregs). indeed, some nutrients could regulate the plasticity and the function of tregs, and be involved in the control of some autoimmune diseases in animals models thanks to a direct effect on immune cells of the digestive tract or an indirect effect by microbiota modulation. the study hypothesises that lcd may be able to restore residual insulin secretion in some patients by modulating immunity. the metabolic mechanisms leading to the effects described in patients with t1d patients under lcd have not been studied : in particular, there is no data on the evolution of the residual insulin secretion and no immunological parameter has been studied on these patients.


Eligibility criteria:
inclusion criteria: * 18 years old or older * type 1 diabetes for less than 20 years * willing to start a low carbohydrate diet of less than 75 g per day * under continuous glucose monitoring * having been informed about the study and having given their written and informed consent exclusion criteria: * already on a low carbohydrate diet of less than 100 g per day * history of ketoacidosis within the last 5 years, except during diabetes diagnosis * autoimmune disease, except thyroiditis * immunosuppressive treatment * hepatitis b virus, hepatitis c virus or human immunodeficiency virus infection * ongoing cancer or history of cancer within the past 5 years, except in situ cervical cancer or basal cell cancer with early treatment * participation to another interventional study within the past 3 months * pregnancy or breast feeding * no affiliation to a social security scheme * patients subject to legal protection measures * unability to give consent for the study

Keywords: type 1 diabetes low carbohydrate diet ketogenic diet
prevalenc of lumbosacral radiculopathy among physiotherapists of pediatric rehabilitation of pediatric rehabilitation

Conditions: Prevalence, Lumbosacral Radiculopathy

Summary: determine the prevalence of lumbosacral radiculopathy among pediatric physiotherapists in the ministry of health in cairo, egypt.

the aim of current study was to determine the prevalence of lumbosacral radiculopathy among pediatric physiotherapists in the ministry of health in cairo, egypt.

Eligibility criteria:
inclusion criteria: * a) the age of the subjects ranged from 25-40 years old; b) all subjects working in ministry of health in cairo-egypt; c) bmi \<30 exclusion criteria: * they were with history of bone disease, renal, liver or endocrinal disorders; b) having lumbosacral radiculopathy before working as pediatric physiotherapists, c) having trauma in back or accident and pregnant pediatric physiotherapists

Keywords: prevalence, lumbosacral radiculopathy, low back pain.
study on the safety for the newborn of the use of biologics during pregnancy by mothers affected by autoimmune diseases

Conditions: Suspected Damage to Fetus From Biologic Agents

Summary: the goal of the study is to evaluate the effects on the offspring and therefore the safety of using biologic agents during pregnancy and their eventual consequences on children. the effects considered are divided into peri-partum and more long-term effects. demonstration of safety in children born from mothers who received biologics during pregnancy will pave the way of their use in other women affected by autoimmune diseases unresponsive to standard treatment.

biologic agents are a group of genetically engineered drugs that target the immune system and have gained a lot of popularity in recent years. they act by interfering with cytokine function or production, inhibiting the "second signal" required for t-cell activation or by depleting b-cells. they are used for the treatment of a wide variety of diseases including rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus (sle), some types of vasculitis and many more. many of these pathologies occur in young women during child-bearing years and so it is important for these drugs to not only be safe to use for the patient but also during pregnancy for fetus and child. many studies are conducted on their safety for the patients but few studies are present on the safety of use during pregnancy. there are even fewer studies that follow up for long term effects on the children outside of the perinatal period. the goal of the study is to evaluate the effects on the offspring and therefore the safety of using biologic agents during pregnancy and their eventual consequences on children. the effects considered are divided into peri-partum and more long-term effects. demonstration of safety in children born from mothers who received biologics during pregnancy will pave the way of their use in other women affected by autoimmune diseases unresponsive to standard treatment.

Eligibility criteria:
inclusion criteria: * children born from mothers treated with biologic agents exclusion criteria: -
development and validation of a telemonitoring system for high-risk cardiovascular patients

Conditions: Cardiovascular Diseases

Summary: development and validation of a telemonitoring system for high-risk cardiovascular patients. the main purpose of this study is to investigate the beneficial effect of continuous telemonitoring in patients with cardiovascular diseases in different clinical settings (hospitalized patients, ambulant patients, patients during cardiac rehabilitation,...) beside established risk parameters such as hrv (heart rate variability) and dc (deceleration capacity) new risk stratification models should be established from the continuously recorded biosignals.


Eligibility criteria:
inclusion criteria: * decidable male and female patients \> 18 years of age * cardiovascular disease with at least one of the following criteria: * lvef ≤ 40% * cardiac autonomic dysfunction * st. p. myocardial infarction * st. p. cardiopulmonary resuscitation * st. p. pulmonalartery embolism * st. p. decompensated heart failure * informed consent for participation in the clinical trial exclusion criteria: * missing informed consent * pregnant and breast-feeding women
ante-hypophyseal dysfunctions in children following moderate to severe traumatic brain injuries

Conditions: Moderate to Severe Traumatic Brain Injury

Summary: annual incidence of severe traumatic brain injuries (tbi) varies from 180 to 300 out of 100.000. mortality or severe sequelae risk is increased 8 fold after a tbi. studies in adults showed an ante-hypophyseal deficit in 28 to 68 % of patients with a tbi. the most common deficit is growth hormone deficit (ghd); followed by gonadotropic and corticotropic (adrenocorticotropic hormone (acth)) insufficiencies. thyrotropic deficits (thyroid-stimulating hormone (tsh)) are less frequent. from a pathophysiological point of view, the lesional mechanism responsible for hypopituitarisms would be a damage of hypophyseal vessels or hypothalamic-pituitary vessels. the frequency of pituitary deficits and the potential beneficial effects of replacement therapy on quality of life, tiredness, loss of energy and productivity, justify the systematic detection of the deficits in patients with moderate to severe tbi. study hypotheses : at the present time, the lack of data in children does not give us the opportunity to affirm that one part of the symptoms showed by children with post-tbi neuropsychological sequelae, are linked to pituitary deficiency and that they can be improved with a replacement therapy. firstly, it is essential to better understand the natural history of post-tbi pituitary deficiencies, studying the connexion between observed deficiencies in acute and late phase of sequelae.


Eligibility criteria:
inclusion criteria: * children from 2 months to 16 years * in the intensive care unit * tbi : moderate (glasgow coma scale (gcs) between 9 and 12) to severe (gcs \<9), whatever the mechanism involved * informed consent form signed by parents exclusion criteria: * obesity (body mass index (bmi) \> 97th percentile for the age) * patient already under replacement therapy. * patient taking antiepileptic drugs (aeds) * patient with long-term systemic corticotherapy * history of neurological disease or learning difficulties * no covered by a national health insurance

Keywords: traumatic brain injury paediatrics hypopituitarism
heated pool exercise groups for patients with rheumatic diseases

Conditions: Rheumatic Disease

Summary: the purpose of this study is to investigate the effects of heated pool group exercises for patients with inflammatory rheumatic diseases with regard to symptoms (pain, fatigue, stiffness and ability to carry out daily activities).

the patients receive text messages on mobile phones twice a week for circa 40 weeks. the text messages ask for pain, fatigue, stiffness and ability to carry out everyday activities. the patients should respond with a number from 0 to 10, where 0 is no symptoms/no hindering of activity and 10 is worst symptoms/worst hindering of activity.

Eligibility criteria:
inclusion criteria: * referral from a medical doctor to group exercises in heated pool * inflammatory rheumatic joint disease * \> 18 years * stable disease * mobile phone owner * understand and use text messages on mobile phones exclusion criteria: * independent living * joint surgery previous to the study start

Keywords: inflammatory rheumatic joint disease text message > 18 years norwegian speaking
enhancing cognitive control in mild cognitive impairment via non-invasive brain stimulation

Conditions: Mild Cognitive Impairment

Summary: the overall goal of this project is to improve cognitive control abilities in adults with mild cognitive impairment (mci) through a form of non-invasive brain stimulation, transcranial alternating current stimulation (tacs).

30 older adults aged 60-80 years with md-amci were randomized to 8 sessions of transcranial alternating current stimulation (tacs) with simultaneous cognitive control training (cct). the intervention took place within the participant's home without direct researcher assistance. half of the participants received prefrontal theta tacs during cct and the other half received control tacs. outcomes were assessed pre and post intervention.

Eligibility criteria:
inclusion criteria: * english speaking * grade 12 or more education * normal or corrected to normal vision and hearing * ability to complete cognitive tasks * ability to cooperate and comply with all study procedures * ability to tolerate tacs * montreal cognitive assessment score: 17-28 * -1 z-score on immediate memory, delayed memory, fluency, processing speed, or task switch * self-reported memory complaint exclusion criteria: * neurological or psychiatric disorders other than mild cognitive impairment * receiving investigational medications or have participated in a trial with investigational medications within last 30 days * family history of epilepsy * implanted electronic devices (e.g., pacemaker) * prior head trauma * pregnant * iq \< 80 * taking cholinesterase inhibitory, memantine, or psychotropic medication * taking anti-depressants or anti-anxiety medication * color blind * substance abuse * glaucoma * macular degeneration * amblyopia (lazy eye) * strabismus (crossed eyes)
study of high density lipoprotein function in type 1 diabetic patients with nephropathy

Conditions: Type 1 Diabetes

Summary: a number of arguments suggest that the deterioration in high density lipoproteins (hdl) functioning may worsen with the development of nephropathy during type 1 diabetes (t1d). the objective of this study will be to investigate to what extent nephropathy in t1d patients in the microalbuminuria and macroalbuminuria stages, compared to t1d patients without nephropathy, is associated with an alteration in hdl functionality and changes in hdl size and composition (lipids with detailed study of phosphates and sphingolipids, main lipoproteins, inflammatory markers).


Eligibility criteria:
inclusion criteria: inclusion criteria group c (controls) : * age \> 18 years * a person who has given oral consent * non-diabetics * fasting plasma glucose \< 6.10 mmol/l (1.1 g/l) * triglyceridemia \< 1.7 mmol/l (1.5 g/l) * hdl-c concentration \> 1.30 mmol/l (for women and 1.03 mmol/l for men) * glomerular filtration flow rate \> 90 ml/min/1.73m2 (these thresholds correspond to the standard thresholds for these parameters) inclusion criteria group t1d-n (with normal albuminuria) : * age \> 18 years * a person who has given oral consent * diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma c-peptide less than 0.5 ng/l) * hba1c between 6 and 9%. * normal albuminuria (albumin/creatinine ratio \< 2.5 mg/mmol in men and \< 3.5 in women) * glomerular filtration rate \> 90 ml/min/1.73m2 inclusion criteria group t1d-micro (with microalbuminuria) * age \> 18 years * a person who has given oral consent * diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma c-peptide less than 0.5 ng/l) * hba1c between 6 and 9%. * microalbuminuria (albumin/creatinine ratio \> 2.5 mg/mmol in men and \> 3.5 in women, and \< 30 mg/mmol) * glomerular filtration rate \> 90 ml/min/1.73m2 inclusion criteria group t1d-macro (with macroalbuminuria) * age \> 18 years * a person who has given oral consent * diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma c-peptide less than 0.5 ng/l) * hba1c between 6 and 9%. * macroalbuminuria (albumin/creatinine ratio \> 30 mg/mmol) * glomerular filtration rate \> 45 ml/min/1.73m2 exclusion criteria: * protected adult * patient not affiliated to a social security scheme * pregnant or breastfeeding woman * drugs interfering with lipid metabolism outside insulin for dt1 : hypolipidemic (only for patients included in the dt1-micro group), corticosteroid, estroprogestogens, retinoic acid, antiproteases. * bmi \> 30 kg/m2
adapted dialectical behaviour therapy for adolescents with deliberate self-harm: a pre-post observational study

Conditions: Deliberate Self Harm; Borderline Personality Disorder

Summary: the investigators conducted a pre-post naturalistic study regarding changes observed associated with a 15-week course of an adapted form of dialectical behaviour therapy for adolescents. we measured frequency of self-harm prior to treatment and after treatment using the self-injurious thoughts and behaviors interview. we also measured changes using the suicide ideation questionnaire, life problems inventory, resiliency scale for children and adolescents.


Eligibility criteria:
inclusion criteria: * features of borderline personality disorder (bpd) and recent history of self-injurious thoughts or behaviours. 1. meeting criteria for bpd or for subsyndromal variants of bpd, and (2) self-injurious thoughts and behaviours defined as: (a) a score \> 30 on the suicidal ideation questionnaire (siq) or (b) deliberate self-harm in the 4 months prior to treatment exclusion criteria: * severe substance use (where residential treatment would be indicated), florid psychosis and developmental delay